CONRAD 138 (ENRICH): Phase I Trial of Continuous or Interrupted 90-Day TFV/LNG Vaginal Ring in Women Without HIV

January 27-28 and February 3-4, 2021
Both tenofovir and levonorgestrel met concentration targets in a 90-day trial assessing the TFV/LNG vaginal ring vs placebo, supporting further study of the TFV/LNG ring for HIV prevention.
Format: Microsoft PowerPoint (.ppt)
File Size: 200 KB
Released: February 6, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) faculty Dr David Malebranche’s expert commentary on racial disparities in HIV care and strategies for improving patient engagement

David Malebranche, MD, MPH Released: September 15, 2021

Download CCO slides reviewing clinically relevant new data reported at IAS 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Daniel R. Kuritzkes, MD
Released: September 13, 2021

Downloadable CCO slides from Daniel R. Kuritzkes, MD, on investigational HIV management approaches, including ARVs, bNAbs, vaccines, and cure

Babafemi Taiwo, MBBS
Program Director
Daniel R. Kuritzkes, MD
Released: September 9, 2021

Clinical Care Options (CCO): Dr Deniz Gökengin on Eastern European studies on HIV services and prevention during COVID-19, presented at IAS 2021

Deniz Gökengin, MD Released: September 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue